BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38071554)

  • 21. A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC).
    Peterson LM; Kurland BF; Schubert EK; Link JM; Gadi VK; Specht JM; Eary JF; Porter P; Shankar LK; Mankoff DA; Linden HM
    Mol Imaging Biol; 2014 Jun; 16(3):431-40. PubMed ID: 24170452
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition.
    Boers J; Venema CM; de Vries EFJ; Glaudemans AWJM; Kwee TC; Schuuring E; Martens JWM; Elias SG; Hospers GAP; Schröder CP
    Eur J Cancer; 2020 Feb; 126():11-20. PubMed ID: 31891878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The value of PET/CT with FES or FDG tracers in metastatic breast cancer: a computer simulation study in ER-positive patients.
    Koleva-Kolarova RG; Greuter MJ; van Kruchten M; Vermeulen KM; Feenstra T; Buskens E; Glaudemans AW; de Vries EF; de Vries EG; Hospers GA; de Bock GH
    Br J Cancer; 2015 May; 112(10):1617-25. PubMed ID: 25880006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo imaging of brain estrogen receptors in rats: a 16α-18F-fluoro-17β-estradiol PET study.
    Khayum MA; de Vries EF; Glaudemans AW; Dierckx RA; Doorduin J
    J Nucl Med; 2014 Mar; 55(3):481-7. PubMed ID: 24481026
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacodynamic imaging guides dosing of a selective estrogen receptor degrader.
    Heidari P; Deng F; Esfahani SA; Leece AK; Shoup TM; Vasdev N; Mahmood U
    Clin Cancer Res; 2015 Mar; 21(6):1340-7. PubMed ID: 25609068
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Application of 18 F-FES PET in Clinical Cancer Care : A Systematic Review.
    Huang YT; Chen TW; Chen LY; Huang YY; Lu YS
    Clin Nucl Med; 2023 Sep; 48(9):785-795. PubMed ID: 37482660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improved Estrogen Receptor Assessment by PET Using the Novel Radiotracer
    Paquette M; Lavallée É; Phoenix S; Ouellet R; Senta H; van Lier JE; Guérin B; Lecomte R; Turcotte ÉE
    J Nucl Med; 2018 Feb; 59(2):197-203. PubMed ID: 28798032
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Head-to-Head Evaluation of
    Ulaner GA; Jhaveri K; Chandarlapaty S; Hatzoglou V; Riedl CC; Lewis JS; Mauguen A
    J Nucl Med; 2021 Mar; 62(3):326-331. PubMed ID: 32680923
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Assessment of Estrogen Receptor Status and Its Intratumoral Heterogeneity in Patients With Breast Cancer by Using 18F-Fluoroestradiol PET/CT.
    Yang Z; Sun Y; Xu X; Zhang Y; Zhang J; Xue J; Wang M; Yuan H; Hu S; Shi W; Zhu B; Zhang Y
    Clin Nucl Med; 2017 Jun; 42(6):421-427. PubMed ID: 28221191
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Nienhuis HH; van Kruchten M; Elias SG; Glaudemans AWJM; de Vries EFJ; Bongaerts AHH; Schröder CP; de Vries EGE; Hospers GAP
    J Nucl Med; 2018 Aug; 59(8):1212-1218. PubMed ID: 29602822
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies.
    Venema CM; Mammatas LH; Schröder CP; van Kruchten M; Apollonio G; Glaudemans AWJM; Bongaerts AHH; Hoekstra OS; Verheul HMW; Boven E; van der Vegt B; de Vries EFJ; de Vries EGE; Boellaard R; Menke van der Houven van Oordt CW; Hospers GAP
    J Nucl Med; 2017 Dec; 58(12):1906-1912. PubMed ID: 28912144
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recommendations and Technical Aspects of 16α-[18F]Fluoro-17β-Estradiol PET to Image the Estrogen Receptor In Vivo: The Groningen Experience.
    Venema CM; Apollonio G; Hospers GA; Schröder CP; Dierckx RA; de Vries EF; Glaudemans AW
    Clin Nucl Med; 2016 Nov; 41(11):844-851. PubMed ID: 27607175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [18F]FDG and [18F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant.
    Iqbal R; Yaqub M; Bektas HO; Oprea-Lager DE; de Vries EGE; Glaudemans AWJM; Aftimos P; Gebhart G; Beelen AP; Schuit RC; Windhorst AD; Boellaard R; Menke-van der Houven van Oordt CW
    Clin Cancer Res; 2023 Jun; 29(11):2075-2084. PubMed ID: 36735488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [18F]-fluoroestradiol quantitative PET imaging to differentiate ER+ and ERα-knockdown breast tumors in mice.
    Paquette M; Ouellet R; Archambault M; Croteau É; Lecomte R; Bénard F
    Nucl Med Biol; 2012 Jan; 39(1):57-64. PubMed ID: 22079037
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SNMMI Procedure Standard/EANM Practice Guideline on Pediatric
    Vali R; Alessio A; Balza R; Borgwardt L; Bar-Sever Z; Czachowski M; Jehanno N; Kurch L; Pandit-Taskar N; Parisi M; Piccardo A; Seghers V; Shulkin BL; Zucchetta P; Lim R
    J Nucl Med; 2021 Jan; 62(1):99-110. PubMed ID: 33334912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of estrogen expression of breast cancer using
    Seenu V; Sharma A; Kumar R; Suhani S; Prashanth A; Mathur S; Parshad R
    World J Nucl Med; 2020; 19(3):233-239. PubMed ID: 33354178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can fluorine-18 fluoroestradiol positron emission tomography-computed tomography demonstrate the heterogeneity of breast cancer in vivo?
    Yang Z; Sun Y; Zhang Y; Xue J; Wang M; Shi W; Zhu B; Hu S; Yao Z; Pan H; Zhang Y
    Clin Breast Cancer; 2013 Oct; 13(5):359-63. PubMed ID: 23787040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Potential of Estrogen and Progesterone Receptor Imaging.
    Linden HM; Peterson LM; Fowler AM
    PET Clin; 2018 Jul; 13(3):415-422. PubMed ID: 30100079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of Dural Metastases Before the Onset of Clinical Symptoms by 16α-[18F]Fluoro-17β-Estradiol PET in a Patient With Estrogen Receptor-Positive Breast Cancer.
    Boers J; Schröder CP; Hospers GAP; de Vries EFJ; Glaudemans AWJM
    Clin Nucl Med; 2021 Mar; 46(3):e165-e167. PubMed ID: 33181752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of the novel estrogen receptor PET tracer 4-fluoro-11β-methoxy-16α-[(18)F]fluoroestradiol (4FMFES) by PET imaging in a breast cancer murine model.
    Paquette M; Phoenix S; Ouellet R; Langlois R; van Lier JE; Turcotte EE; Bénard F; Lecomte R
    Mol Imaging Biol; 2013 Oct; 15(5):625-32. PubMed ID: 23619898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.